Market Research Report
Generic Drugs Market in Japan 2015-2019
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||324488|
|Published||Content info||94 Pages
Delivery time: 1-2 business days
|Generic Drugs Market in Japan 2015-2019|
|Published: February 11, 2015||Content info: 94 Pages||
This publication has been discontinued on January 14, 2020.
A generic drug is a duplicate of brand-name drugs and has the same dosage form, active ingredient(s), potency, route of administration, quality, and intended use as that of branded drugs. Generic drugs enter the market once the patent protection of the original developer expires. Generally, the cost of generic drugs is 50-70 percent lower than that of their brand-name counterparts, while meeting the very same standards of safety, quality, and efficacy as the innovator drugs. Generic drugs help the manufacturer by eliminating the need to develop and market a new drug. As the patent approaches expiration, manufacturers can apply to the FDA for approval to manufacture and sell generic versions of the drug. Generic drugs are equal to and within the bioequivalence range of branded drugs.
TechNavio's analysts forecast the Generic Drugs market in Japan to grow at a CAGR of 8.16 percent over the period 2014-2019.
The Generic Drugs market in Japan can be divided into three segments: Generic Prescription Medicines, Super Generics, and Biosimilars. This report covers the present scenario and the growth prospects of the Generic Drugs market in Japan for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the following segments:
TechNavio's report, the Generic Drugs market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the Generic Drugs market in Japan and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.